Article
Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up.
Antiviral therapy - 1 Mar 2000
Clevenbergh P, Durant J, Halfon P, del Giudice P, Mondain V, Montagne N, Schapiro J M, Boucher C A, Dellamonica P
Abstract excerpt
OBJECTIVE: We report the 12 months follow-up of the patients who participated in the Viradapt study. METHODS: A total of 108 HIV-infected patients failing antiretroviral (ARV) therapy (HIV RNA > 10,000 copies/ml, therapy > 6 months with nucleoside reverse transcriptase inhibitors, > 3 months with protease inhibitors (PIs) were randomized into two arms: standard of care in the control arm, and treatment according...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.